Inhibition of growth hormone and glucagon release by Phe-4-somatostatin in patients with acromegaly

A. L. Charro; J. A. Cabranes; A. Lafuente; C. Diaz-Salgado; M. Cordero; I. Almoguera; A. M. Comaru-Schally; C. A. Meyers; D. H. Coy; A. V. Schally

Inhibition of growth hormone and glucagon release by Phe-4-somatostatin in patients with acromegaly

A. L. Charro, J. A. Cabranes, A. Lafuente, C. Diaz-Salgado, M. Cordero, I. Almoguera, A. M. Comaru-Schally, C. A. Meyers, D. H. Coy, A. V. Schally

Research output: Contribution to journal › Article

Abstract

We have studied growth hormone (GH), insulin (I), glucagon (Gl) and glucose in basal conditions, after somatostatin (SS) (3 μg/ml) and Phe-4-SS (0.75 μg/ml) infusion and IV bolus of the latter in 3 acromegalic patients. In two patients, Phe-4-SS inhibited glucagon and growth hormone secretion in a similar way to SS, without modifying insulin secretion. These effects were short-lived and ceased after the infusion was stopped. From these results it appears that Phe-4-SS is both more potent and more specific than SS with respect to inhibition of GH and glucagon release, but it does not have prolonged biological action. Lack of suppression of GH by SS or Phe-4-SS in the acromegalic patient with post-surgical recurrence of the disease could be due to the existence of receptor abnormalities, and suggests a diversity in the physiopathology of the disease.

Original language	English (US)
Pages (from-to)	432-444
Number of pages	13
Journal	Research Communications in Chemical Pathology and Pharmacology
Volume	45
Issue number	3
State	Published - Nov 15 1984
Externally published	Yes

ASJC Scopus subject areas

Pathology and Forensic Medicine
Toxicology
Pharmacology
Pharmacology, Toxicology and Pharmaceutics(all)

Access to Document

Fingerprint Dive into the research topics of 'Inhibition of growth hormone and glucagon release by Phe-4-somatostatin in patients with acromegaly'. Together they form a unique fingerprint.

Cite this

Charro, A. L., Cabranes, J. A., Lafuente, A., Diaz-Salgado, C., Cordero, M., Almoguera, I., Comaru-Schally, A. M., Meyers, C. A., Coy, D. H., & Schally, A. V. (1984). Inhibition of growth hormone and glucagon release by Phe-4-somatostatin in patients with acromegaly. Research Communications in Chemical Pathology and Pharmacology, 45(3), 432-444.

Inhibition of growth hormone and glucagon release by Phe-4-somatostatin in patients with acromegaly. / Charro, A. L.; Cabranes, J. A.; Lafuente, A.; Diaz-Salgado, C.; Cordero, M.; Almoguera, I.; Comaru-Schally, A. M.; Meyers, C. A.; Coy, D. H.; Schally, A. V.

In: Research Communications in Chemical Pathology and Pharmacology, Vol. 45, No. 3, 15.11.1984, p. 432-444.

Research output: Contribution to journal › Article

Charro, A. L. ; Cabranes, J. A. ; Lafuente, A. ; Diaz-Salgado, C. ; Cordero, M. ; Almoguera, I. ; Comaru-Schally, A. M. ; Meyers, C. A. ; Coy, D. H. ; Schally, A. V. / Inhibition of growth hormone and glucagon release by Phe-4-somatostatin in patients with acromegaly. In: Research Communications in Chemical Pathology and Pharmacology. 1984 ; Vol. 45, No. 3. pp. 432-444.

@article{2b3b7ddf87d4453bb0a31f155b164d65,

title = "Inhibition of growth hormone and glucagon release by Phe-4-somatostatin in patients with acromegaly",

abstract = "We have studied growth hormone (GH), insulin (I), glucagon (Gl) and glucose in basal conditions, after somatostatin (SS) (3 μg/ml) and Phe-4-SS (0.75 μg/ml) infusion and IV bolus of the latter in 3 acromegalic patients. In two patients, Phe-4-SS inhibited glucagon and growth hormone secretion in a similar way to SS, without modifying insulin secretion. These effects were short-lived and ceased after the infusion was stopped. From these results it appears that Phe-4-SS is both more potent and more specific than SS with respect to inhibition of GH and glucagon release, but it does not have prolonged biological action. Lack of suppression of GH by SS or Phe-4-SS in the acromegalic patient with post-surgical recurrence of the disease could be due to the existence of receptor abnormalities, and suggests a diversity in the physiopathology of the disease.",

author = "Charro, {A. L.} and Cabranes, {J. A.} and A. Lafuente and C. Diaz-Salgado and M. Cordero and I. Almoguera and Comaru-Schally, {A. M.} and Meyers, {C. A.} and Coy, {D. H.} and Schally, {A. V.}",

year = "1984",

month = nov,

day = "15",

language = "English (US)",

volume = "45",

pages = "432--444",

journal = "Research Communications in Molecular Pathology and Pharmacology",

issn = "0034-5164",

publisher = "PJD Publications Ltd",

number = "3",

}

TY - JOUR

T1 - Inhibition of growth hormone and glucagon release by Phe-4-somatostatin in patients with acromegaly

AU - Charro, A. L.

AU - Cabranes, J. A.

AU - Lafuente, A.

AU - Diaz-Salgado, C.

AU - Cordero, M.

AU - Almoguera, I.

AU - Comaru-Schally, A. M.

AU - Meyers, C. A.

AU - Coy, D. H.

AU - Schally, A. V.

PY - 1984/11/15

Y1 - 1984/11/15

N2 - We have studied growth hormone (GH), insulin (I), glucagon (Gl) and glucose in basal conditions, after somatostatin (SS) (3 μg/ml) and Phe-4-SS (0.75 μg/ml) infusion and IV bolus of the latter in 3 acromegalic patients. In two patients, Phe-4-SS inhibited glucagon and growth hormone secretion in a similar way to SS, without modifying insulin secretion. These effects were short-lived and ceased after the infusion was stopped. From these results it appears that Phe-4-SS is both more potent and more specific than SS with respect to inhibition of GH and glucagon release, but it does not have prolonged biological action. Lack of suppression of GH by SS or Phe-4-SS in the acromegalic patient with post-surgical recurrence of the disease could be due to the existence of receptor abnormalities, and suggests a diversity in the physiopathology of the disease.

AB - We have studied growth hormone (GH), insulin (I), glucagon (Gl) and glucose in basal conditions, after somatostatin (SS) (3 μg/ml) and Phe-4-SS (0.75 μg/ml) infusion and IV bolus of the latter in 3 acromegalic patients. In two patients, Phe-4-SS inhibited glucagon and growth hormone secretion in a similar way to SS, without modifying insulin secretion. These effects were short-lived and ceased after the infusion was stopped. From these results it appears that Phe-4-SS is both more potent and more specific than SS with respect to inhibition of GH and glucagon release, but it does not have prolonged biological action. Lack of suppression of GH by SS or Phe-4-SS in the acromegalic patient with post-surgical recurrence of the disease could be due to the existence of receptor abnormalities, and suggests a diversity in the physiopathology of the disease.

UR - http://www.scopus.com/inward/record.url?scp=0021203196&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0021203196&partnerID=8YFLogxK

M3 - Article

C2 - 6150529

AN - SCOPUS:0021203196

VL - 45

SP - 432

EP - 444

JO - Research Communications in Molecular Pathology and Pharmacology

JF - Research Communications in Molecular Pathology and Pharmacology

SN - 0034-5164

IS - 3

ER -